C84.69
Anaplastic large cell lymphoma, ALK-positive, extranodal and solid organ sites
Clinical Classification Guidelines
Medical Intelligence & Overview
Anaplastic large cell lymphoma (ALCL), ALK-positive, is a rare type of non-Hodgkin lymphoma, a cancer that originates in the lymphatic system. This condition is characterized by the abnormal growth of large lymphocyte cells that can spread quickly through various tissues and organs. The term 'ALK-positive' indicates that the cancer cells test positive for a genetic marker called anaplastic lymphoma kinase (ALK), which plays a role in the growth of the lymphoma. ALCL often involves extranodal sites, meaning it can affect areas outside of the lymph nodes, such as organs and tissues, which can complicate treatment and management.
Causes & Symptoms
Clinical Causes: Genetic mutations involving the ALK gene, leading to the abnormal growth of lymphocytes. Possible environmental factors or exposures, though specific causes remain largely unknown. A combination of genetic predisposition and environmental influences may contribute, but research is ongoing to clarify these links.
Key Symptoms: Swelling in lymph nodes, especially in the neck, armpits, or groin. Presence of a lump or mass that may be painless or tender. B symptoms: fever, night sweats, and unexplained weight loss. Fatigue and general feeling of weakness. Skin rashes, skin nodules, or itching if the skin is involved. Signs of organ involvement such as abdominal pain or discomfort, depending on affected sites. Shortness of breath or cough, if the lungs are involved. Pain or swelling in the affected extranodal sites, which could include the liver, spleen, or bones.
Diagnostic & Treatment
Diagnosis Path: Diagnosis typically involves a combination of clinical evaluation and laboratory tests. A biopsy of the affected tissue is essential to confirm the presence of ALCL. The tissue sample undergoes microscopic examination and immunophenotyping to identify the characteristic large lymphocytes. Additionally, genetic testing for ALK gene rearrangements is performed, as ALK-positive status influences prognosis and treatment options. Imaging techniques such as CT scans, PET scans, or MRI help determine the extent of the disease and whether it has spread to other sites. Blood tests may also be used to assess overall health and organ function.
Treatment Protocols: Management of ALK-positive anaplastic large cell lymphoma generally involves systemic therapies, primarily chemotherapy. Targeted treatments such as ALK inhibitors are also available for cases expressing this marker, offering a more personalized approach. In some instances, stem cell transplantation may be considered, especially in cases that do not respond to initial treatment. Supportive care to address symptoms, prevent infections, and manage side effects of therapy is also an essential part of the treatment plan. The prognosis varies depending on factors such as disease stage, patient health, and response to therapy, but advances in treatment have improved outcomes for many patients.
Clinical Advice & FAQs
Billing Guidance
Is C84.69 a billable ICD-10 code?
Yes, C84.69 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report C84.69?
Clinical documentation must specify the nature of Anaplastic large cell lymphoma, ALK-positive, extranodal and solid organ sites and any associated comorbidities for accurate reporting.
Cite this Clinical Reference